While some have hailed the adoption of digital health by pharma, that’s not my impression, at least on the R&D side. In my view, it remains very much on the “innovation initiative” side of things, rather than a clear business need (like pharmacology); drug development companies may be dipping their toes in and celebrating their bravery, but at best they are interested – certainly not what I’d call “pig committed.”